Package Leaflet: Information for the User
SIMBRINZA 10mg/ml+2mg/ml eye drops, suspension
brinzolamide/brimonidine tartrate
Read the package leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the package leaflet
SIMBRINZA contains two active substances, brinzolamide and brimonidine tartrate. Brinzolamide belongs to a group of medicines called carbonic anhydrase inhibitors and brimonidine tartrate belongs to a group of medicines called alpha-2 adrenergic receptor agonists. Both active substances work together to reduce the pressure in the eye.
SIMBRINZA is used to reduce pressure in the eyes in adult patients (18 years of age and older) with eye diseases known as glaucoma or ocular hypertension, and in those who cannot be adequately controlled with a single medication.
Do not use SIMBRINZA
Warnings and precautions
Talk to your doctor, ophthalmologist (eye specialist) or pharmacist before you start using SIMBRINZA if you currently have or have had in the past:
Be careful with SIMBRINZA:
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported in association with brinzolamide treatment. Stop using SIMBRINZA and seek immediate medical attention if you notice any of the symptoms related to these severe skin reactions described in section 4.
If you wear soft contact lenses, do not use this eye drop with the contact lenses in place. See below under the section "If you wear contact lenses - SIMBRINZA contains benzalkonium chloride".
Children and adolescents
SIMBRINZA is not indicated for use in children and adolescents under 18 years of age because it has not been studied in this age group. It is especially important that this medicine is not used in children under 2 years of age (see previous section "Do not use SIMBRINZA") because it is unlikely to be safe.
Other medicines and SIMBRINZA
Tell your doctor, ophthalmologist (eye specialist) or pharmacist if you are using, have recently used, or might use any other medicines.
SIMBRINZA may affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.
Ask your doctor if you are using or plan to use any of the following medicines:
You should also tell your doctor if the dose of any of your current medicines changes.
Using SIMBRINZA with alcohol
If you regularly drink alcohol, talk to your doctor, ophthalmologist (eye specialist), or pharmacist before using this medicine. SIMBRINZA may be affected by alcohol.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or plan to become pregnant, talk to your doctor, ophthalmologist (eye specialist), or pharmacist before using this medicine. Women who may become pregnant are advised to use effective contraceptive methods during treatment with SIMBRINZA. The use of SIMBRINZA is not recommended during pregnancy. Do not use SIMBRINZA unless clearly indicated by your doctor.
If you are breastfeeding, SIMBRINZA may pass into breast milk. The use of SIMBRINZA is not recommended during breastfeeding.
Driving and using machines
Immediately after applying SIMBRINZA, you may notice that your vision becomes blurred or abnormal. SIMBRINZA may also cause dizziness, drowsiness, or fatigue in some patients.
Do not drive or use machines until the symptoms have resolved.
If you wear contact lenses - SIMBRINZA contains benzalkonium chloride
This medicine contains 0.15 mg of benzalkonium chloride per 5 ml, which is equivalent to 0.03 mg/ml.
Benzalkonium chloride can be absorbed by soft contact lenses and may alter the color of the contact lenses. Remove the contact lenses before using this medicine and wait 15 minutes before putting them back. Benzalkonium chloride may cause eye irritation, especially if you have dry eyes or other corneal diseases (the transparent layer on the front of the eye). Talk to your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medicine.
Follow the instructions for administration of this medicine exactly as indicated by your doctor, ophthalmologist (eye specialist), or pharmacist. If you are unsure, talk to your doctor, ophthalmologist (eye specialist), or pharmacist again.
Use SIMBRINZA only in your eyes. Do not swallow or inject.
The recommended doseis one drop in the affected eye(s) twice a day. Use it at the same time each day.
How to use
Wash your hands before starting.
1 2
Shake well before use.
Remove the cap from the bottle. After removing the cap, the security seal ring must be removed before using this medicine.
Do not touch the dropper tip with your fingers when opening or closing the bottle, because the drops may become contaminated.
Hold the bottle upside down between your thumb and index finger.
Tilt your head back.
Gently pull down the lower eyelid to form a pocket for the drop (figure 1).
Bring the tip of the bottle close to the eye. You can use a mirror to help you.
Do not touch the eye, eyelid, or surrounding areas with the dropper tip, because the drops may become contaminated.
Gently press the base of the bottle to release one drop of SIMBRINZA.
Do not squeeze the bottle: it is designed to release one drop with a gentle pressure on the base (figure 2).
After using this eye drop, close your eyes and press the edge of the eye, next to the nose, for at least 2 minutes. This helps prevent the medicine from entering the rest of the body.
If you are putting drops in both eyes, repeat the above steps for the other eye. You do not need to close and shake the bottle between administrations for both eyes. Replace the cap on the bottle immediately after use.
If you are using other eye drops as well as SIMBRINZA, wait at least 5 minutes between applying SIMBRINZA and the other drops.
If a drop misses the eye, try again.
If you use more SIMBRINZA than you should
You can rinse your eyes with warm water. Do not apply more drops until it is time for the next dose.
Adults who accidentally ingested medicines containing brimonidine experienced a decrease in heart rate, a decrease in blood pressure that may be followed by an increase in blood pressure, heart failure, difficulty breathing, and effects on the nervous system. If this happens, contact your doctor immediately.
Severe side effects were reported in children who accidentally ingested medicines containing brimonidine. The signs included sleepiness, floppiness, low body temperature, paleness, and difficulty breathing. If this happens, contact your doctor immediately.
If you have accidentally ingested SIMBRINZA, contact your doctor immediately.
If you forget to use SIMBRINZA
Continue with the next scheduled dose. Do not apply a double dose to make up for the missed doses. Do not apply more than one drop twice a day in the affected eye(s).
If you stop using SIMBRINZA
Do not stop using SIMBRINZA without talking to your doctor first, because the pressure in your eye may not be controlled, which could lead to loss of vision.
If you have any other questions about using this medicine, ask your doctor, ophthalmologist (eye specialist), or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, stop using this medicine and seek immediate medical attention, as they may be signs of an allergic reaction to the medicine. The frequency of an allergic reaction to this medicine is not known (cannot be estimated from the available data).
Contact your doctor immediately if you feel dizzy or extremely tired.
The following side effects have been observed with SIMBRINZA and with other medicines that contain brinzolamide or brimonidine alone.
Stop using SIMBRINZA and seek immediate medical attention if you notice any of the following symptoms:
red spots, target-shaped or circular, on the trunk, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes. These severe skin rashes may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from the available data)
Reporting side effects
If you experience any side effects, talk to your doctor, ophthalmologist (eye specialist), or pharmacist, even if they are not listed in this package leaflet. You can also report side effects directly through the national reporting system listed in Annex V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after "EXP". The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
To avoid infections, discard the bottle 4 weeks after first opening. Write the opening date on the space provided on the carton.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
SIMBRINZA composition
Very small amounts of sodium hydroxide and/or hydrochloric acid are added to maintain normal acidity levels (pH levels).
Product appearance and container contents
SIMBRINZA eye drops in suspension are a liquid (a uniform white to off-white suspension) that comes in a box containing one or three 5 ml plastic bottles with a screw cap.
Only some pack sizes may be marketed.
Marketing authorization holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Manufacturer
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Manufacturing NV
Rijksweg 14
2870 Puurs-Sint-Amands
Belgium
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Siegfried El Masnou, S.A.
Camil Fabra 58
El Masnou
08320 Barcelona
Spain
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva Novartis Pharma Services Inc. Tel: +370 5 269 16 50 |
България Novartis Pharma Services Inc. Тел.: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 26 37 82 111 |
Eesti Novartis Pharma Services Inc. Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλάδα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: + 421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Κύπρος Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija Novartis Pharma Services Inc. Tel: +371 67 887 070 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu
The average price of SIMBRINZA 10mg/ml + 2mg/ml ophthalmic suspension in October, 2025 is around 18.06 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.